Nanobiotix/ Malaysian Biotech explain collaboration

Nanobiotix, an emerging French nanomedicine company focused on cancer therapy, and its partner, Malaysian Biotechnology Corp (BiotechCorp), will focus their collaboration on developing point-of-care diagnostics and drug delivery systems for tropical diseases, such as malaria. BiotechCorp has acquired an exclusive, global license to a Nanobiotix nanotechnology platform for non-cancer purposes. As part of the collaboration, three of its scientists will take up residence at Nanobiotix for a period of 12 months to undergo the technology transfer training.

Malaria is a disease that can be transmitted to people of all ages through the bites of infected mosquitoes. Approximately 40% of the world's population is at risk of the disease. Every year, more than 500 million people worldwide become severely ill with malaria. Early diagnosis and effective treatment will shorten its duration and prevent the development of complications and the great majority of deaths from malaria, the companies note.